Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGTX Cognition Therapeutics	$2.76 +38.8%	$0.71	$0.22 ▼ $2.70	$201.97M	1	4.69 million shs	15.77 million shs
CMMB Chemomab Therapeutics	$0.91 +2.4%	$1.09	$0.87 ▼ $2.55	$17.09M	0.52	225,360 shs	226,348 shs
MGX Metagenomi	$1.94 +4.6%	$1.92	$1.23 ▼ $4.92	$72.62M	-0.12	680,841 shs	205,157 shs
ZIVO ZIVO Bioscience	$15.21 -11.6%	$13.99	$7.61 ▼ $22.15	$58.06M	-0.06	1,070 shs	2,864 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGTX Cognition Therapeutics	-1.49%	+19.88%	+156.67%	+570.26%	+165.40%
CMMB Chemomab Therapeutics	-3.59%	-1.37%	-20.98%	-35.16%	-27.46%
MGX Metagenomi	0.00%	-2.63%	-20.60%	+14.20%	-44.28%
ZIVO ZIVO Bioscience	0.00%	-5.60%	+29.81%	-4.44%	+102.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGTX Cognition Therapeutics	3.3393 of 5 stars	3.6	4.0	3.3	1.7	0.6
CMMB Chemomab Therapeutics	3.2793 of 5 stars	3.5	5.0	2.4	1.7	0.6
MGX Metagenomi	2.2431 of 5 stars	3.5	2.0	1.6	1.7	0.6
ZIVO ZIVO Bioscience	0.2751 of 5 stars	0.0	3.0	0.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGTX Cognition Therapeutics	3.25	Buy	$2.83	2.55% Upside
CMMB Chemomab Therapeutics	3.00	Buy	$8.50	838.19% Upside
MGX Metagenomi	3.00	Buy	$10.00	416.80% Upside
ZIVO ZIVO Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CMMB, CGTX, MGX, and ZIVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	MGX Metagenomi	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
8/15/2025	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
8/14/2025	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $12.00
8/8/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/26/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/27/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.10 per share	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$0.51 per share	N/A
MGX Metagenomi	$52.29M	1.39	N/A	N/A	$5.22 per share	0.37
ZIVO ZIVO Bioscience	$15.85K	3,662.88	N/A	N/A	($0.81) per share	-18.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGTX Cognition Therapeutics	-$33.97M	-$0.67	N/A	N/A	N/A	N/A	-251.23%	-130.75%	N/A
CMMB Chemomab Therapeutics	-$13.94M	-$0.59	N/A	N/A	N/A	N/A	-94.71%	-76.53%	N/A
MGX Metagenomi	-$78.06M	-$2.36	N/A	N/A	N/A	-257.99%	-37.84%	-27.15%	N/A
ZIVO ZIVO Bioscience	-$7.78M	-$2.58	N/A	∞	N/A	N/A	N/A	-2,240.92%	N/A

Latest CMMB, CGTX, MGX, and ZIVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CMMB Chemomab Therapeutics	-$0.20	-$0.09	+$0.11	-$0.09	N/A	N/A
8/12/2025	Q2 2025	MGX Metagenomi	-$0.68	-$0.54	+$0.14	-$0.54	$7.72 million	$8.51 million
8/7/2025	Q2 2025	CGTX Cognition Therapeutics	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGTX Cognition Therapeutics	N/A	1.54	1.54
CMMB Chemomab Therapeutics	N/A	7.42	5.33
MGX Metagenomi	N/A	6.36	6.36
ZIVO ZIVO Bioscience	N/A	0.17	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGTX Cognition Therapeutics	43.35%
CMMB Chemomab Therapeutics	46.05%
MGX Metagenomi	N/A
ZIVO ZIVO Bioscience	12.83%

Insider Ownership

Company	Insider Ownership
CGTX Cognition Therapeutics	14.40%
CMMB Chemomab Therapeutics	11.91%
MGX Metagenomi	17.80%
ZIVO ZIVO Bioscience	48.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGTX Cognition Therapeutics	20	73.47 million	62.89 million	Not Optionable
CMMB Chemomab Therapeutics	20	18.86 million	16.61 million	Not Optionable
MGX Metagenomi	236	37.53 million	30.85 million	N/A
ZIVO ZIVO Bioscience	10	3.82 million	2.91 million	Not Optionable

CMMB, CGTX, MGX, and ZIVO Headlines

Recent News About These Companies

ZIVO Bioscience (NASDAQ:ZIVO) Stock Price Crosses Above 50-Day Moving Average - Should You Sell?

August 22 at 4:30 AM | marketbeat.com

Analyzing ZIVO Bioscience (NASDAQ:ZIVO) & Protalix BioTherapeutics (NYSE:PLX)

August 15, 2025 | americanbankingnews.com

ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry

June 20, 2025 | businesswire.com

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 7, 2025 | finance.yahoo.com

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 6, 2025 | businesswire.com

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

February 6, 2025 | businesswire.com

Zivo Bioscience issues new shares, raises $1.5 million

January 28, 2025 | msn.com

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

January 1, 2025 | investing.com

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

December 20, 2024 | businesswire.com

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023

March 18, 2024 | investorplace.com

Harmony Biosciences Holdings

March 4, 2024 | forbes.com

Regencell Bioscience Holdings Ltd RGC

February 1, 2024 | morningstar.comM

ZIVO Bioscience Announces Uplisting to OTCQB Market

January 29, 2024 | finance.yahoo.com

Ideaya Biosciences

January 18, 2024 | forbes.com

Dare Bioscience Inc DARE

January 14, 2024 | morningstar.comM

Zivo Bioscience Inc (ZIVO) USD0.001

November 11, 2023 | hl.co.uk

Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72

November 1, 2023 | msn.com

Zivo Bioscience Inc ZIVO

November 1, 2023 | morningstar.comM

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

October 30, 2023 | finance.yahoo.com

Zivo Bioscience Announces 1-for-6 Reverse Stock Split To Regain Compliance

October 26, 2023 | markets.businessinsider.com

Zivo Bioscience to effect reverse stock split to regain compliance with Nasdaq rules

October 26, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB, CGTX, MGX, and ZIVO Company Descriptions

Cognition Therapeutics NASDAQ:CGTX

$2.76 +0.77 (+38.84%)

As of 03:35 PM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Chemomab Therapeutics NASDAQ:CMMB

$0.91 +0.02 (+2.37%)

As of 03:33 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Metagenomi NASDAQ:MGX

$1.94 +0.09 (+4.59%)

As of 03:33 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

ZIVO Bioscience NASDAQ:ZIVO

$15.21 -1.99 (-11.57%)

As of 01:08 PM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time